St John's Institute of Dermatology, School of Basic and Medical Biosciences, King's College London, Guy's Hospital, London, United Kingdom; Institute of Dermatology, Ministry of Public Health, Bangkok, Thailand.
St John's Institute of Dermatology, School of Basic and Medical Biosciences, King's College London, Guy's Hospital, London, United Kingdom; Department of Dermatology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan; International Center for Wound Repair and Regeneration, National Cheng Kung University, Tainan, Taiwan.
J Invest Dermatol. 2020 Mar;140(3):624-635.e7. doi: 10.1016/j.jid.2019.08.441. Epub 2019 Sep 4.
Dermatofibromas are common benign skin lesions, the etiology of which is poorly understood. We identified two unrelated pedigrees in which there was autosomal dominant transmission of multiple dermatofibromas. Whole exome sequencing revealed a rare shared heterozygous missense variant in the F13A1 gene encoding factor XIII subunit A (FXIII-A), a transglutaminase involved in hemostasis, wound healing, tumor growth, and apoptosis. The variant (p.Lys679Met) has an allele frequency of 0.0002 and is predicted to be a damaging mutation. Recombinant human Lys679Met FXIII-A demonstrated reduced fibrin crosslinking activity in vitro. Of note, the treatment of fibroblasts with media containing Lys679Met FXIII-A led to enhanced adhesion, proliferation, and type I collagen synthesis. Immunostaining revealed co-localization between FXIII-A and α4β1 integrins, more prominently for Lys679Met FXIII-A than the wild type. In addition, both the α4β1 inhibitors and the mutation of the FXIII-A Isoleucine-Leucine-Aspartate-Threonine (ILDT) motif prevented Lys679Met FXIII-A-dependent proliferation and collagen synthesis of fibroblasts. Our data suggest that the Lys679Met mutation may lead to a conformational change in the FXIII-A protein that enhances α4-integrin binding and provides insight into an unexpected role for FXIII-A in the pathobiology of familial dermatofibroma.
纤维瘤是常见的良性皮肤病变,其病因尚不清楚。我们在两个无关联的家系中发现了多发性纤维瘤的常染色体显性遗传。全外显子组测序显示,编码因子 XIII 亚单位 A(FXIII-A)的 F13A1 基因存在罕见的共同杂合错义变异,FXIII-A 是一种参与止血、伤口愈合、肿瘤生长和细胞凋亡的转谷氨酰胺酶。该变异(p.Lys679Met)的等位基因频率为 0.0002,预计为致病变异。重组人 Lys679Met FXIII-A 在体外表现出降低的纤维蛋白交联活性。值得注意的是,用含有 Lys679Met FXIII-A 的培养基处理成纤维细胞会导致黏附、增殖和 I 型胶原合成增强。免疫染色显示 FXIII-A 与 α4β1 整合素共定位,Lys679Met FXIII-A 比野生型更为明显。此外,α4β1 抑制剂和 FXIII-A 的异亮氨酸-亮氨酸-天冬氨酸-苏氨酸(ILDT)基序的突变均可阻止 Lys679Met FXIII-A 依赖性成纤维细胞增殖和胶原合成。我们的数据表明,Lys679Met 突变可能导致 FXIII-A 蛋白构象发生变化,增强 α4-整合素结合,并深入了解 FXIII-A 在家族性纤维瘤病发病机制中的意外作用。